Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9538070 | 0.77 | HTT (0.30) | HTT | |
| SCHEMBL9539762 | 0.77 | HTT (0.47) | AHRSMN1; SMN2CYP3A4MAPTALDH1A1 | |
| SCHEMBL2388664 | 0.77 | ALDH1A1 (0.39) | AHRSMN1; SMN2CYP3A4MAPTALDH1A1 | |
| SCHEMBL3482864 | 0.76 | ALDH1A1 (0.44) | AHRSMN1; SMN2CYP3A4MAPTALDH1A1 | |
| SCHEMBL3483178 | 0.74 | ALDH1A1 (0.40) | SMN1; SMN2MAPTALDH1A1HTTTSHR | |
| SCHEMBL3483297 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP3A4MAPTALDH1A1HTT | |
| SCHEMBL3078539 | 0.70 | HTT (0.38) | CYP3A4MAPTALDH1A1HTTTSHR | |
| SCHEMBL24817 | 0.68 | ALDH1A1 (0.54) | AHRSMN1; SMN2ALDH1A1HTTCYP1A2 | |
| SCHEMBL3482926 | 0.67 | ATM (0.47) | — | |
| SCHEMBL5652739 | 0.67 | AHR (0.47) | AHRSMN1; SMN2MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111747981-A | Transition metal compound and preparation method and application thereof | 万华化学集团股份有限公司 | 2020-10-09 | — | — | CN | claimed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | claimed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | claimed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | claimed |
| EP-1828207-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006066174-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1007518-A4 | SOLID AND LIQUID-PHASE SYNTHESIS OF BENZOXAZOLES AND BENZOTHIAZOLES AND THEIR USE | SEPRACOR INC (US) | 2002-11-06 | — | — | EP | claimed |
| US-6177572-B1 | 2-AMIDOPHENOL OR 2-AMIDOTHIOPHENOL IS COUPLED TO A SOLID PHASE SUPPORT THROUGH A LINKER GROUP, SUCH THAT A BENZOXAZOLE OR A BENZOTHIAZOLE IS FORMED | SEPRACOR, INC. | 2001-01-23 | — | — | US | claimed |
| EP-1007518-A1 | SOLID AND LIQUID-PHASE SYNTHESIS OF BENZOXAZOLES AND BENZOTHIAZOLES AND THEIR USE | SEPRACOR, INC. (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999009017-A1 | SOLID AND LIQUID-PHASE SYNTHESIS OF BENZOXAZOLES AND BENZOTHIAZOLES AND THEIR USE | SEPRACOR INC. (US) | 1999-02-25 | — | — | WO | claimed |
| CN-111747981-A | Transition metal compound and preparation method and application thereof | 万华化学集团股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-7692046-B2 | Heterogeneous arylalkyl oxidation promoter | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
| EP-0004532-B1 | 1-ARYLOXY-3-NITRATOALKYLAMINO-2-PROPANOLS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | MERCK PATENT GmbH (DE) | 1981-10-14 | — | — | EP | disclosed |
| US-4288452-A | 1-Aryloxy-3-nitratoalkylamino-2-propanols and use as β-receptor blocker | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-09-08 | — | — | US | disclosed |
| EP-0004532-A1 | 1-Aryloxy-3-nitratoalkylamino-2-propanols, process for their preparation and pharmaceutical compositions | MERCK PATENT GmbH (DE) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | AHR 71/4885SMN1; SMN2 2461/4885CYP3A4 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.